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Abstract There is a pressing need to develop new anti-
viral treatments; of the 60 drugs currently available, half
are aimed at HIV-1 and the remainder target only a further
six viruses. This demand has led to the emergence of
possible peptide therapies, with 15 currently in clinical
trials. Advancements in understanding the antiviral poten-
tial of naturally occurring host defence peptides highlights
the potential of a whole new class of molecules to be
considered as antiviral therapeutics. Cationic host defence
peptides, such as defensins and cathelicidins, are important
components of innate immunity with antimicrobial and
immunomodulatory capabilities. In recent years they have
also been shown to be natural, broad-spectrum antivirals
against both enveloped and non-enveloped viruses,
including HIV-1, influenza virus, respiratory syncytial
virus and herpes simplex virus. Here we review the anti-
viral properties of several families of these host peptides
and their potential to inform the design of novel
therapeutics.
1 Antiviral Peptide Treatments
Viral diseases are a leading cause of morbidity and mor-
tality worldwide, particularly of children [1], and yet
development of effective therapies is slow. In particular,
progress is hampered by the fact that the majority of
antiviral drugs are specific for only one virus. Current
approaches are expensive, require rapid identification of
the virus before therapy and, at the initial stages of
development, involve enormous redundancy of research
effort. This also results in efforts being concentrated on a
few viruses; of the 60 antiviral drugs that have so far been
approved by the US Food and Drug Administration (FDA),
almost half target HIV-1; the remaining half are used for
the treatment of hepatitis B virus (HBV), herpes simplex
virus (HSV), varicella-zoster virus (VZV), cytomegalovi-
rus (CMV), influenza (IAV) and hepatitis C virus (HCV)
infections [2].
These factors, in combination with the rate of develop-
ment of drug resistance, mean that there is an urgent need
for new broader-spectrum intervention strategies. It is
therefore exciting that in recent years a new class of anti-
viral therapeutic peptides are emerging, with 15 peptide-
based intervention strategies against viruses currently in
various stages of clinical trials [3]. Peptide-based strategies
are proposed to be cost-effective, with peptides having low
molecular weights, rapid elimination following treatment,
and low levels of side effects [3].
An exciting current area of advancement is in under-
standing the antiviral properties of naturally occurring
cationic host defence peptides (CHDPs) and the capacity of
this to inform the design of novel synthetic antiviral ana-
logues. In this review we will give an overview of the
antiviral activities of CHDPs and consider their potential in
the development of broad-spectrum antiviral therapeutics.
2 Cationic Host Defence Peptides
CHDPs, also known as antimicrobial peptides, are an
essential part of the innate immune response, with both
direct microbicidal and pleiotropic immunomodulatory
properties [4–6]. Their fundamental importance to host
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defence against infection is emphasised by their conser-
vation across plants, insects, reptiles, birds and fungi [7]. In
mammals the two major families of CHDPs are defensins
and cathelicidins.
2.1 a-Defensins
Defensins are cationic, amphipathic peptides generated
from prepropeptides via proteolysis and are categorised
within three subfamilies: a, b and h. Defensins were first
characterised as ‘‘natural peptide antibiotics’’ with the
discovery of a-defensins from the granules of neutrophils
[8].
The a-defensin family has been identified in a range of
higher eukaryotes (including primates, mice, rats, guinea
pigs and rabbits) and comprises six distinct peptides in
humans (human neutrophil peptides (HNP) 1–4 and
human defensins (HD) 5–6), expressed from five DEFA
genes [9]. All have a triple-stranded b-sheet core stabi-
lised by three intramolecular disulphide bonds, and are
made first as a prepropeptide which is proteolytically
cleaved to the active form [10]. In the case of HD5 and
HD6 the key protease is trypsin. HNP1–4 are produced
mainly by neutrophils, where they comprise 5–7 % of
total neutrophil protein [11], and neutrophil precursors in
the bone marrow [12]. HNP1–3 are also described in NK
cells, B cells, cd T cells, macrophages and immature
dendritic cells [13], but can be acquired from neutrophils
[14]. The release of active HNPs from neutrophil azuro-
philic granules can be induced by a range of stimuli,
including chemokines, FC gamma receptor cross linking,
PMA and TLR stimulation [13]. In contrast, HD5 and 6
are expressed by Paneth cells of the small intestine [15,
16] and epithelial cells of the female genital tract [12, 17,
18]. Interestingly, although mice express a large number
of intestinal a-defensins (cryptdins) [19], in contrast to
humans they do not express a-defensins in their neutro-
phils [20, 21].
a-Defensins have well-described broad spectrum anti-
microbial activity against both Gram-positive and -nega-
tive organisms in vitro [22], with cationicity and
hydrophobicity being shown to be key determinants of
these properties [9, 23]. Their cationic charge is proposed
to enable interaction with the net negative charge on the
surface of the Gram-negative bacteria and the teichoic
acids of the Gram-positive organisms, while their amphi-
pathic structure enables insertion into and disruption of the
bacterial membranes, leading to lysis of the cells. In
addition, various a-defensins are described as having
additional, non-microbicidal properties, including chemo-
taxis for effector cells of the innate and adaptive immune
systems [24, 25], inhibition of macrophage pro-inflammatory
cytokines [26], modulation of the intestinal microbiome [27]
and the formation of protective peptide nanonets [28].
2.2 b-Defensins
The b-defensin family contains more than 30 members in
humans and more than 50 in mice, and are widely
expressed across many species, in particular being the only
defensins found in birds and with close homologues present
in snakes, platypus and sea anemones [29]. They are
also triple-stranded b-sheet proteins, but differ from the
a-family members in the organisation and arrangement of
the three disulphide bonds [10]. The most well character-
ised human b-defensins are human b-defensin (HBD) 1–3,
expressed by epithelial cells [30], monocytes, macrophages
and macrophage-derived DC [31]. HBD1 is encoded by
DEFB1 and is expressed constitutively [30], whereas
expression of HBD2 (DEFB4A) and HBD3 (DEFB103A)
are up-regulated in response to various inflammatory
stimuli, including microbes [32], TLR and NOD proteins
[33] and pro-inflammatory cytokines [34].
b-Defensins are also described as having broad-spec-
trum antimicrobial activity in vitro [7], with potency
varying in different family members. Interestingly, the
weak microbicidal properties of HBD1 were recently
shown to be greatly enhanced upon reduction of its disul-
phide bonds [35]. Although relatively mild phenotypes
were found in mouse models deficient in Defb1 [36, 37],
redundancy in this multi-gene family may be responsible
for this observation. In addition b-defensins are described
as having a range of immunomodulatory properties,
including chemotaxis of CD4? memory T cells, macro-
phages and immature dendritic cells [38], enhancement of
wound healing [39] and the modulation of inflammatory
cytokine responses (with the capacity both to promote and
to suppress inflammation in different settings) [40].
2.3 h-Defensins
h-Defensins are circular octadecapeptides, the only circular
peptides of mammalian origin [41], formed by the splicing of
two nonapeptides, each of which contributes three cysteines
to a series of disulphide bonds in the mature peptide [42].
Three h-defensins have been found in the leukocytes of
rhesus macaques and named RTD1-3, but although six RNA
transcripts homologous to RTD are found in the human bone
marrow they contain a premature stop codon preventing their
expression [42, 43]. However, an artificially constructed
peptide based on these pseudogenes, called retrocyclin, has
been studied with respect to its function and therapeutic
potential and shown to kill Escherichia coli in the same way
as a-defensins, by permeabilising its membrane [44].
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2.4 Cathelicidins
The cathelicidin family is quite distinct from defensins;
cathelicidins are defined by a conserved cathelin domain
and with a variable C-terminal region, which is proteo-
lytically cleaved to produce a mature functional peptide,
with a range of structural forms in different family
members [45]. In contrast to the extensive defensin fam-
ily, humans (and mice, rats and rabbits) express a single
cathelicidin, whereas multiple cathelicidins are found in
other species (e.g. protegrins in pigs). The sole human
cathelicidin, human cationic antimicrobial peptide of
18 kDa (hCAP-18; encoded by the CAMP gene), is
cleaved by proteinase 3 into its active form, LL-37, which
is a cationic, amphipathic peptide of 4.5 kDa with an
a-helical structure [46, 47]. hCAP-18 is stored in neutro-
phil-specific granules, inducible in epithelial cells, mac-
rophages and other leukocytes to a lesser extent, and
detectable in a range of body fluids, including airway
surface liquid, plasma, urine, breast milk and sweat [48].
It is up-regulated in response to infectious and inflam-
matory signals [49] and wounding [50] and its expression
can be increased by vitamin D metabolites [51] and
compounds such as butyrate [52].
LL-37 has well-documented antibacterial potential;
however, when studied in the presence of physiological
concentrations of cations or serum, LL-37 has high mini-
mum inhibitory concentrations compared to levels descri-
bed in vivo [6]. Mice deficient in mCRAMP (encoded by
the Camp gene, the orthologue of CAMP) have increased
susceptibility to infections in multiple systems, including
the skin, intestinal tract and lung [53–55]. Although these
models clearly demonstrate the critical role for cathelicidin
in host defence against infection, it remains unclear to what
extent this is due to microbicidal or modulatory properties
of the peptide. LL-37 has been shown to have a broad
range of immunomodulatory and inflammomodulatory
properties [6]. These include chemotactic activity for
neutrophils, monocytes and T cells [56], modulation of
cytokine production [57], effects on dendritic cell differ-
entiation and function [58, 59], promotion of wound
healing [60] and angiogenesis [61], and modulation of cell
death [62, 63].
3 Antiviral Activity of a-Defensins
Although the field of antimicrobial peptide research has
been dominated by evaluation of the antibacterial activities
of these peptides, early studies evaluating the antiviral
potential of human a-defensins showed promise and have
been followed by an increasing level of research interest
(Fig. 1).
3.1 Herpes Simplex Virus
The first paper detailing an antiviral role was published
27 years ago, describing inhibition of a number of viruses
including HSV types 1 and 2, cytomegalovirus and vesic-
ular stomatitis virus by HNP1 in vitro [64]. In particular, it
demonstrated direct antiviral activity of HNP1 against
HSV-1 in a temperature- and pH-dependent manner,
inhibited by serum, but interestingly less sensitive to the
inhibitory effects of cations than the more broadly studied
antibacterial properties.
HNP1–4, HD5 and HD6 have subsequently been found
to be active against HSV-2 (up to approximately 1 log
decrease at 50 lg/ml) by preventing viral binding to either
glycoprotein B (gB2) or heparan sulphate (the primary
receptor for HSV) [65]. gB2 binding capacity was found to
be primarily determined by peptide sequence rather than
net cationic charge [66], with lectin-like properties likely to
be key to the glycoprotein binding functions [67]. Inter-
estingly, those defensins (HNP1–3 and HBD5) which
bound viral envelope gB were also found to be effective at
preventing infection if added after viral entry, even up to
8 h post-infection (with HNP1 or HD5), suggesting addi-
tional later stage effects on viral replication [65]. Further-
more, cumulative effects were observed with repeated
application of peptide, reducing infection with HSV by
greater than 7 logs at 100 lg/ml. These features make
a-defensins of considerable interest as potential exogenous
vaginal microbicides, with a proof of concept study in mice
demonstrating protection against HSV following gel-based
application of HD5 [65].
3.2 HIV-1
a-Defensins have been demonstrated to directly inactivate
HIV-1, with the observation of reduced cytopathogenicity
in a CD4? T cell line [68]. Although confusion existed
following the retraction of a paper proposing that a-
defensins were the key component of the CD8 antiviral
factor CAF [69, 70], it is worth noting that the retraction
related to the source of the a-defensins (probably
‘‘imported’’ into CD8 cells from co-cultured cells), and the
anti-HIV-1 properties of the peptides were not called into
question. Indeed, the potential of a-defensins to treat HIV
was reinforced when it was found that breast milk a-de-
fensin concentration is significantly associated with a
decreased risk of intrapartum and postnatal HIV trans-
mission [71].
Recent studies demonstrate that multiple steps in the
entry of HIV-1 virus into cells are disrupted by HNP1 [72].
This peptide has been shown to bind to CD4 and to the env
glycoprotein on the virus, thus inducing the down-regula-
tion of CD4 and CXCR4 and blocking interaction of env
Antiviral Potential of Host Defence Peptides 481
with the co-receptors. By targeting particular conforma-
tions of env it also inhibited late fusion steps [72]. HNP1–3
can bind to CD4 and HIV-1 gp120 with high affinity;
however, HNP4, which is a much weaker binder, is a more
potent inhibitor, meaning this aspect of direct inhibition is
not, currently, entirely clear [73]. Mechanistic studies have
shown that HNP1–3 can also inhibit steps following
reverse transcription and integration by inhibiting PKC
activity; PKC is important for HIV replication as it up-
regulates transcription through NF-jB activation and Tat
phosphorylation, as well as regulating fusion and assembly
of the virions [74]. It is worth noting that in these studies
the direct effects on the virus particles occurred only in the
absence of serum; in its presence, these mechanisms were
inhibited and effects are instead on the host cells, resulting
in inhibited replication of the virus [69, 74–76]. Defensins
can also stimulate an antiviral state in cells by promoting
secretion of chemokines [76]. In macrophages this up-
regulation of chemokines also contributes to inhibition of
HIV through competition for receptors [76].
A potential issue with using defensins as a topical
antiviral treatment is that, despite CHDPs (including
defensins) being required for in vitro anti-HIV activity of
vaginal fluid from healthy women, defensins may also
cause immune activation and subsequent loss of CD4? T
cells by apoptosis, and may indirectly enhance HIV
transmission [77]. In particular, it is known that HNP2 and
HBD2 are both chemotactic for DC and induce infiltration
of DC into cultures of HPV-transformed keratinocytes and
subsequent immune activation [78]. In addition, HD5 and
6, which are produced by cervico-vaginal epithelial cells
[18] and present at up to 50 lg/ml in the vaginal fluid of
healthy women [79], enhance HIV infectivity in vitro by
promoting the virus attachment to target cells [18, 79].
Thus, the balance of these effects remains to be
determined.
3.3 Influenza A Virus
a-Defensins are also found in high concentrations in the
inflamed lung, generating interest in their potential activi-
ties against respiratory viruses. HNP1–3 are the most
abundant antimicrobial peptides in airway fluid [80] and
are up-regulated further following infection or inflamma-
tion [81] as they are produced by both immigrating neu-
trophils and airway epithelial cells [82].
Daher et al. [64] first described antiviral effects of HNP1
against the WSN strain of IAV in vitro, showing a fairly
modest approximately 0.5 log reduction at 50 lg/ml. This
property of HNP1 and 2 was later confirmed in other
strains of IAV (with decreased infectivity of approximately
1 log at 10 lg/ml in a fluorescent focus assay of infectiv-
ity). The peptides were shown to have no activity in a
haemagglutinin inhibition assay [83], but to induce
aggregation of IAV [84]. Interestingly HNP aggregation of
the PR8 viral strain was much higher than that of the Phil82
strain, which has greater surface glycosylation [84–86], and
neutralising activity of HNPs was greater against PR8 than
against Phil82 [83], suggesting the reduced carbohydrate
attachments on the envelope proteins allow greater
Fig. 1 Antiviral activities of a-
defensins. a-Defensins have
antiviral activity against herpes
simplex virus (HSV), human
immunodeficiency virus (HIV),
influenza A virus (IAV), human
papillomavirus (HPV) and
adenovirus (Adv), via a range of
different mechanisms
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interaction with the defensins. However, direct effects of
HNP1 on IAV viral particles were found to have no impact
on viral growth in infected cultures [87]. Maximal antiviral
effects in this study (1–3 logs at 5–25 lg/ml HNP1 in a
range of cell lines) required interaction of HNP1 with the
eukaryotic cells before infection and the continued pres-
ence of peptide in the culture system. Nevertheless, in
contrast to pretreatment of virus, pretreatment of the cells
did induce some protection.
This suggests the predominant mechanism of action is
cell-mediated, and has been proposed to be a consequence
of HNP-mediated inhibition of PKC activity (essential for
endosomal trafficking of the IAV) [87, 88]. The capacity of
a-defensin to protect against IAV was lost in its linearised
analogue [87]. In addition to effects on IAV infection of
epithelial cells, HNP1 and 2 at approximately 40 lg/ml
(but not HNP3, HBD2 or 3) can enhance the uptake of IAV
by neutrophils, following pre-incubation of either the cells
or the virus with the defensins [84]. However, this modu-
lation of neutrophil phagocytic capacity was also observed
using bacteria, and was not virus specific.
These properties of a-defensins suggest potential as
templates for novel therapeutics. However, their ability to
bind surfactant protein D (SP-D) may be of concern, hav-
ing mixed competitive or co-operative, and IAV strain-
dependent effects on the antiviral activities of SP-D [83].
HNPs (but not b-defensins) can bind and precipitate
bronchoalveolar lavage (BAL) fluid SP-D [83, 89] and may
account for SP-D depletion from the lung in diseases with
chronic neutrophilic inflammation.
3.4 Non-Enveloped Viruses
It was originally suggested that a-defensins had no activity
against non-enveloped viruses, on the basis of the absence
of effects against echovirus type II and reovirus type 3 [64].
However, more recent work has demonstrated inhibition of
non-enveloped viruses such as adenovirus, human papil-
lomavirus (HPV) [90–92] and BK virus [93].
The mechanisms underpinning these antiviral effects
against non-enveloped viruses appear to be distinct from
those targeting enveloped viruses. A study of HPV (uti-
lising pseudovirus particles) found normal binding,
uncoating and internalisation in the presence of a-defen-
sins; however, the peptides prevented the virion from
escaping the endocytic vesicles [92]. The antiviral activity
was observed using HNP1–4 (and the cathelicidin LL-37),
was maximal using HD5, but was not observed using HD6.
The sensitivity of adenoviruses to a-defensin-mediated
neutralisation is serotype-dependent [90, 94]. HNP1 and
HD5 have been shown to inhibit human adenovirus
infection in both lung and conjunctival epithelial cells by
inhibiting an early step in viral entry [90, 91, 95, 96]. Two
arginine residues on one face of HD5 were found to be
critical for antiviral activity, with Arg-28 necessary for
killing of both AdV and HPV and Arg-9 for AdV only [97].
Viral aggregation is not sufficient for neutralisation and
binding of a-defensin to the adenoviral virus capsid
appears to be critical, preventing uncoating in the cell and
hence entry of the viral genome into the nucleus [97, 98].
In contrast, the antiviral effects of HNP1 and HD5 on the
BK polyomavirus appear to primarily relate to viral
aggregation preventing receptor binding on the host cells
[93].
4 Antiviral Activity of b-Defensins
b-Defensins can be induced in both humans and mice
following viral infection. mBD3 and 4 (orthologues of
HBD2) are murine b-defensins which are induced in vivo
during influenza virus (IAV) infection in mice [99],
whereas HIV-1 infection induced HBD2 and 3 expression
in normal human oral epithelium, even if the virus was not
replicating [100]. Similarly, human rhinovirus (HRV)
replication in human bronchial epithelial cells induces NF-
jB-dependent HBD2 and 3 expression (but not HBD1)
[101, 102], whereas respiratory syncytial virus (RSV) can
induce HBD2 in an NF-jB-dependent, but IFN type
1-independent manner in human lung epithelial cells [103].
The extent to which these innate responses are functionally
effective against the viral pathogens is starting to be elu-
cidated (Fig. 2).
4.1 Herpes Simplex Virus
In contrast to the effects of a-defensins, only one of the b-
defensins tested (HBD3) had appreciable effects against
HSV [65]. HBD3 was found to inhibit HSV-2 infection of
human cervical epithelial cells (by approximately 1 log at
10 lg/ml) by interfering with the viral binding and pene-
tration processes by binding both gB and heparan sulphate.
In contrast, HBD1 and HBD2 had low affinity to gB and
cellular glycosaminoglycans, and were not able to reduce
HSV-2 infectivity. However, only HD5 was applied in vivo
in this study [65].
4.2 HIV-1
HIV-1 infection of epithelial cells induces HBD2 and 3
expression in vitro [100] and in buccal mucosal cells
in vivo [104], and both inhibit HIV transmission through
multiple mechanisms [100, 105]. Both down-regulate the
co-receptor CXCR4 expression (but not CCR5) on the
surface of CD4? T cells via an increase in internalisation
[106]. In addition, there are both direct effects on the
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virions in a concentration-dependent manner [100] and on
intracellular, post-viral entry inhibition [105].
However, in large-scale studies, copy number variation
of total b-defensin gene number positively correlates with
HIV load in Ethiopian and Tanzanian patients [107]. The
authors suggest that the chemoattractant nature of b-
defensins may bring the target Th17 cells into mucosal
sites where they can be readily infected by virus. Other
work, however, has recently shown that exposed but
seronegative individuals have much higher HBD2 and 3
copy numbers in oral mucosa (but not vaginal mucosa)
than healthy controls, indicating a role for these defensins
in combating infection [108].
4.3 Influenza A Virus
Although not normally regarded as inducible, expression of
HBD1 (but not HBD2, 3 or 4) has been observed in pri-
mary human blood-derived plasmacytoid DC and mono-
cytes following infection with IAV [109]. In contrast, an
early decrease in expression of this peptide was found in
IAV-infected epithelial cell lines [109]. Recombinant
HBD1 was found to have antiviral effects in vitro
(approximately 1.5 log decrease at 50 lg/ml). However,
despite evidence of a significant defect in host defence
against IAV in Defb1-deficient mice, this did not extend to
differences in viral load, suggesting a primary role of
immunomodulatory properties in vivo [109]. IAV has been
found to up-regulate expression of murine defensins mBD3
and mBD4 in upper and lower airways, as well as tran-
scription of the genes encoding mBD1 and mBD2 in the
lung [99], also suggesting protective roles for these pep-
tides. Recombinant mBD2 [110] and mBD3 [111] pro-
tected MDCK cells against infection with IAV PR8 strain
(up to approximately 1 log decrease at 100 lg/ml); this
protection was effective during binding or internalisation
of the virus, but not after viral entry. Furthermore, repeated
intranasal administration of recombinant mBD2 (2 mg/kg;
optimal when premixed with virus before infection) or
intravenous delivery of recombinant mBD3 (10 mg/kg)
was found to be protective in murine lethal infection
models [110, 111]. The latter study also suggested that the
effects may relate to immunomodulatory properties, with
systemic mBD3 treatment up-regulating IFN-c and IL-12
and reducing levels of TNF. Thus, although b-defensins
can inhibit influenza virus infectivity (albeit less potently
than the a-defensins or LL-37) [89], immunomodulatory
properties, perhaps also including up-regulation of IAV
uptake by neutrophils [84], may prove to be key to their
protective function against this virus in vivo and future
therapeutic developments.
4.4 Respiratory Syncytial Virus
In addition to effects on IAV, evidence has been found for
b-defensin activity against RSV, another important respi-
ratory virus, for which no effective vaccine or antiviral
treatments exist. In studies using the A549 human lung cell
Fig. 2 Antiviral activities of b-
defensins. b-Defensins have
antiviral activity against herpes
simplex virus (HSV), human
immunodeficiency virus (HIV),
influenza A virus (IAV),
respiratory syncytial virus
(RSV) and vaccinia virus (VV),
via a range of different
mechanisms
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line, HBD2 was identified as a component of an NF-jB-
dependent, IFN-a/b-independent antiviral response [103].
Epithelial cell HBD2 production was induced in response
to RSV replication and also in response to the TNF
secreted by infected epithelial cells. HBD2, but not HBD1,
was found to protect against RSV infection (approximately
2 log decrease at 4 lg/ml), by blocking viral cellular entry
[103]. Destabilisation of the viral envelope was proposed to
occur upon contact with soluble HBD2 in solution, or
following exposure to plasma membrane-associated HBD2
during cell entry. In addition to lung epithelial cells,
myeloid cells can produce high levels of TNF in response
to RSV infection [112]. This has the potential to up-regu-
late HBD2 expression in the airway lumen and might
consequently modulate protection against RSV infection
and limit virus spread. Interestingly mBD4 (but not mBD3;
both considered homologues to HBD2) was found to be up-
regulated in vivo in the murine lung in response to RSV
infection [103].
4.5 Vaccinia Virus
HBD3 has been proposed to have antiviral activity against
vaccinia virus [113]. However, HNP1, HBD1 and HBD2
are unable to neutralise the virus [114]. Pre-exposure of
virus to synthetic HBD3 for 24 h decreased infection of the
BSC-1 monkey kidney cell line, shown both by reduced
levels of DNA-dependent RNA polymerase expression and
plaque formation (approximately 1 log decrease at 10 lM)
[113], although the mechanism remains to be elucidated.
Up-regulation of HBD3 expression was observed in
response to vaccinia virus infection in primary human
keratinocytes, but this could be inhibited by IL-4 and IL-13.
Interestingly, these cytokines are associated with pathology
in atopic dermatitis, a condition in which b-defensin
expression is reduced [115] and patients are at risk of
developing eczema vaccinatum caused by vaccinia virus.
5 Antiviral Activity of h-Defensins
Circular h-defensins were identified in the leukocytes and
bone marrow of macaques (Rhesus h-defensins; RTD)
[116] and discovered to have effective antibacterial activ-
ity. Humans were found to have at least six h-defensin
genes (DEFT genes) [117], but none produce a translated
protein, owing to insertion of a premature stop codon.
Putative ancestral human h-defensins, named retrocyclins
(RC), were developed and their antimicrobial properties
were tested [117]. In addition to activity against Pseudo-
monas aeruginosa, E. coli, Listeria monocytogenes and
Staphylococcus aureus, antiviral potential has also been
described (Fig. 3).
5.1 Herpes Simplex Virus
Both rhesus h-defensins and retrocyclins (including RTD3,
RC1 and RC2) have been found to inhibit HSV-1 and
HSV-2 infection of human cervical epithelial cell lines
following pre-incubation of virus and peptide [66]. How-
ever, RC2 was found to have no direct virucidal properties
[118], but to be active irrespective of pre-incubation by
blocking attachment and cell penetration of HSV [66]. This
activity resulted from peptide binding to gB2, in a manner
dependent on the presence of sialic acid and carbohydrate
moieties in the glycoprotein’s O- and N-linked glycans.
Prophylactic application of RC2 in a murine HSV-medi-
ated ocular keratitis model demonstrated the capacity of
RC2 to modestly reduce viral titres in vivo and reduce
blepharitis, corneal vascularization and stromal disease.
However, RC2 had no effect upon disease pathology when
applied post-infection [118].
5.2 HIV-1
Initial studies on retrocyclins found no direct inactivation
of HIV-1, but demonstrated strong inhibition of proviral
DNA formation and protection of primary human CD4? T
cells from T- and M-tropic HIV-1 strains in vitro [117,
119]. These observations led to a significant body of work
evaluating retrocyclins as HIV treatments. RC1 has been
characterised as a lectin, which protects peripheral blood
Fig. 3 Antiviral activities of h-defensins. h-Defensins have antiviral
activity against herpes simplex virus (HSV), human immunodefi-
ciency virus (HIV), influenza A virus (IAV), SARS coronavirus
(SARS), via a range of different mechanisms
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leukocytes from HIV-1 [117]. This peptide prevents viral
entry into cells [42, 119], blocking formation of the 6-helix
bundle required for fusion, by binding to HIV gp120 and
cellular CD4 through interactions with their O- and N-
linked sugars [120].
Activity of many of the initial retrocyclins produced was
inhibited by serum, minimising usefulness in serum-con-
taining anatomical compartments [42]. However, ana-
logues, each differing from RC1 by a single amino acid
substitution, show greater potential as topical microbicides
[121]. Of these, RC100 was found to inhibit primary CD4?
T cell infection by HIV-1 similarly to RC1, but was active
in the presence of vaginal fluid, and RC101 is significantly
more potent against HIV than RC1; both have potential as
topical microbicides [122]. Interestingly, the rate of escape
mutations of RC100-treated HIV was low; treatment altered
sites in HR1 and HR2 of gp410 but these only reduced
susceptibility by 10-fold, compared to 10,000–20,000-fold
for CCR5 blockade [122]. Using an organ culture model,
RC101 was found to block transmission of two strains of
HIV-1 across cervical mucosa. Antiviral activity was
retained in the presence of semen and vaginal fluid, there
was no cytotoxicity to cervical tissue and, importantly,
RC101 did not induce a pro-inflammatory response, with no
chemotactic activity for immune cells [123]. In addition,
topical intra-vaginal RC101 application in pigtailed maca-
ques was found to be safe and well tolerated, with peptide
retained in the cervical and vaginal tissue for up to 4 days
post-application, no changes in vaginal pH observed and
minimal effects on commensal microbiota [124].
5.3 Respiratory Viruses
The application of retrocyclins to pathogenic respiratory
viruses has also been evaluated. Expression of recombi-
nant RC2 in both MDCK cells and chicken embryos has
been shown to inhibit replication of an H5N1 influenza
virus [125]. In addition, RC1, RC2 and RC101 all had
antiviral activities in studies using MDCK and A549 cell
lines (approximately 1 log decrease at 20 lg/ml against
IAV Phil82, but less effective against PR8 strain) [89].
The retrocyclins were more effective than HBD1 and
HBD2, with potency equivalent to HNP1–3. This study
noted the capacity of the RC peptides to induce aggre-
gation of the virus and increase viral uptake by neutro-
phils and macrophages [89]. RC2 was also found to
inhibit influenza A/X31 infection of cell lines in vitro by
blocking the haemagglutinin-mediated fusion of viral and
endosomal membranes [85]. The inhibition of hemifusion
formation was shown to be a lectin property which
involved cross linking and immobilising surface glyco-
proteins and blocking the protein displacement required to
bridge the bilayers for fusion. RC2 was only effective
when given before viral internalisation, but had antiviral
properties even when only applied to the host cell
membrane.
Interestingly, despite the capacity to bind SP-D, retro-
cyclins increased, rather than inhibited, the antiviral
activity of SP-D [89]. This is in contrast to the a-defensins
[83], and promising for therapeutic use at mucosal sites.
To further improve the antiviral activity of synthetic
retrocyclins against influenza and simplify their structure, a
series of analogues containing 13–14 amino acids, termed
hapivirins and diprovirins, were designed [126]. Some of
these analogues, including HpV1, 8, 11–15, 17, 19 and
DpV 13, 16, 1623 and 1632 proved to be more effective
than RC2 and RC101 against IAV Phil82 (H3N2) and PR-8
(H1N1). Mechanistically analogous to the retrocyclins,
these peptides were found to be active before viral inter-
nalisation, induce viral aggregation, opsonise virus, and
have an additive effect with SP-D. In addition, hapivirins
and diprovirins were shown to inhibit IAV-induced mac-
rophage TNF production, adding immunomodulatory
mechanism to their therapeutic potential.
Antiviral activity of retrocyclins has also been reported
against SARS virus, a coronavirus which infects the alve-
olar epithelial cells and induces rapid severe lung pathol-
ogy [127, 128]. In a mouse model of SARS infection,
RTD-1 treatment increased survival from 25 to 100 %.
Interestingly, this was in the absence of any impact on viral
titres. Instead the cytokine profile of the infected animals
was modified, with increased early (day 2) production of
IL-6 and GM-CSF, but decreased IL-1a, IL-1b, IL-6,
MIP1a, and IL-12p40 by day 4. These data highlight the
possibility that novel peptide therapeutics may be produc-
tively targeted at modulation of the inflammatory response
to infection, rather than developed for virucidal properties
per se. Such an approach may prove to have broad-spec-
trum applicability and lends further support to the potential
for these peptides as novel immunomodulatory antiviral
agents.
6 Antiviral Activity of Cathelicidins
Cathelicidins have been widely studied with regard to their
antibacterial properties and broad array of immunomodu-
latory activities [6]. Although known to be up-regulated in
inflammation and released by neutrophils, their roles in
defence against viral infection and properties as antiviral
agents are less well understood (Fig. 4).
6.1 HIV-1
hCAP-18 is expressed in human epididymal epithelium and
is present at high concentrations in seminal plasma [129]. It
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is also expressed in cervico-vaginal secretions and up-
regulated in participants with bacterial sexually transmitted
infections [130]. Cervico-vaginal LL-37 levels in HIV-
negative individuals who were in HIV sero-discordant
relationships were also found to be greatest in those whose
HIV-positive partners had the highest viral load [131]. LL-
37 has been shown to inhibit the replication of a range of
HIV-1 isolates in primary CD4? T cells [132]. This
occurred in a manner that was independent of change in
expression of any HIV-1 receptors in these cells. A recent
study demonstrated that LL-37 was capable of a dose-
dependent suppression of HIV reverse transcriptase activity
[133]. This study also demonstrated that this function was
retained by a 16 amino acid fragment of LL-37 (17–32),
with implications for production of smaller synthetic ana-
logues. Thus, epithelial expression of LL-37 has been
proposed to contribute to local protection against HIV-1
infection. However, although the cationic peptide fraction
of cervico-vaginal secretions was found to have HIV-1-
neutralising activity, which could be enhanced by addition
of recombinant LL-37, this property did not correlate with
levels of endogenous LL-37 detected [131]. In addition, in
one study LL-37 levels were independently associated with
increased HIV acquisition, although both observations
might be the result of a high prevalence of sexually
transmitted infections in these individuals [130]. Therefore,
the in vivo significance of LL-37 in HIV remains unclear.
6.2 Influenza A Virus
We recently demonstrated that LL-37 has antiviral effects
against IAV, both in vitro and in vivo [134]. Both human
and murine cathelicidins had antiviral activity when pre-
incubated with influenza viruses in vitro [approximately
1 log decrease at 10 lg/ml against A/PR/8/34 (H1N1),
but somewhat less effective against A/Udorn/307/72
(H3N2)]. In addition, LL-37 has recently been shown to
bind IAV, without aggregating or affecting haemaggluti-
nation activity, and to have maximal effects in vitro when
pre-incubated with virus (although delayed addition of
peptide or treatment of the cells, with washing before
infection also has some antiviral effects) [135]. Surpris-
ingly, LL-37 was found not to alter the binding or initial
uptake of virus by cells, but peptide-mediated disruption
of viral membranes (shown by electron microscopy) was
proposed to affect viral propagation or survival down-
stream of this [135].
We demonstrated that aerosolised therapeutic adminis-
tration of either LL-37 or mCRAMP (given every day for
1 week, with an additional pre-infection dose) provided
protection against infection in a mouse model [134].
Peptide-treated mice showed increased survival and
decreased weight loss compared to control infected ani-
mals, and were similarly protected to those treated with
zanamavir (a neuraminidase inhibitor currently used
therapeutically in humans). The cathelicidin-treated mice
showed some decrease in viral loads, but more striking
reductions in lung cytokines (in particular GM-CSF, IL-
1b, KC and CCL5), again suggesting the possibility of a
key immunomodulatory roles in the antiviral efficacy of
such peptides. Scrambled control peptides did not have
these effects but interestingly the D-enantiomers did,
indicating the actions of LL-37 are not solely related to
charge and are likely not reliant on specific receptor
interactions.
The mechanisms by which cathelicidins modulate
inflammation in IAV infection remain unclear, but may
relate to the observation that LL-37 can modulate Toll-
like receptor signalling [136]. Induction of rapid antiviral
responses depends, at least in part, on TLR recognition
of the viral genome, with ssRNA and dsRNA viruses
recognised by TLR7/8 and TLR3 [137]. LL-37 com-
plexed with self DNA and RNA has been shown to
induce TLR7-, TLR8- and TLR9-dependent inflammatory
responses to otherwise non-immunostimulatory nucleic
acids [59, 138]. In addition, LL-37 has been proposed to
enhance [139, 140] or inhibit [141] TLR3-dependent
responses to viral RNA or synthetic mimics. These
modulatory properties may well prove to underpin the
in vivo effects.
Fig. 4 Antiviral activities of cathelicidins. Cathelicidins have anti-
viral activity against human immunodeficiency virus (HIV), influenza
A virus (IAV), respiratory syncytial virus (RSV) and vaccinia virus
(VV), via a range of different mechanisms
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6.3 Respiratory Syncytial Virus
The expression of LL-37/hCAP18 by airway epithelial
cells can be induced in vitro by infection with RSV [142],
in a manner that is significantly enhanced by the 1,25OH
metabolite of vitamin D. In addition, a recent study found
that median serum hCAP-18 levels are significantly lower
in children with RSV bronchiolitis than in children with
bronchiolitis caused by human rhinovirus [143]. Further-
more, RSV-infected children with hCAP-18 levels lower
than the median are more likely to be hospitalised for
prolonged periods than those with hCAP-18 levels above
the median. These findings suggest an important antiviral
role for LL-37 in host innate immune response against
RSV. In keeping with this hypothesis, we have recently
demonstrated that LL-37 exhibits effective, dose-depen-
dent and timing-specific anti-RSV activity in vitro in a
number of cell lines [144]. These data indicate that thera-
peutic use of cathelicidin or strategies to up-regulate
cathelicidin expression in vivo (particularly during the
winter when low vitamin D levels may lead to diminished
cathelicidin expression) may be protective against RSV
infections.
6.4 Vaccinia Virus
Individuals with atopic dermatitis (AD) have low levels of
LL-37 expression and increased susceptibility to skin
infections, in contrast to those with psoriasis, who have
high levels of LL-37 expression and are less prone to skin
infections, despite similar disruption to skin barrier
function [145]. The low levels of LL-37 expression in AD
are proposed to be important in the susceptibility to
eczema vaccinatum, a disseminated viral skin infection
that follows inoculation with vaccinia virus (VV). LL-37
expression was induced in response to VV in normal and
psoriatic skin biopsies, but not those from AD skin [146].
Both LL-37 and mCRAMP have been shown to have
antiviral activity against vaccinia virus in vitro (approxi-
mately 1 log decrease at 25 lM) [114]. These peptides
were shown to damage the integrity of the double-layered
viral envelope [114], by removing the outer membrane
[147]. In addition, Camp-/- mice were found to develop
significantly more pox skin lesions following infection
with VV, demonstrating the antiviral effects of cathelici-
dins in vivo [114]. Interestingly these effects against VV
were found to be specific to cathelicidins, with HNP1,
HBD1 and HBD2 unable to neutralise the virus [114].
This implies that the different CHDPs may have different
(if sometimes overlapping) targets in order to successfully
deal with the enormously wide range of human
pathogens.
7 Conclusion
The antiviral activities of host defence peptides have been
somewhat neglected until recently, in contrast to the study
of their antibacterial effects. Yet, as discussed in this
review, a strong basis exists for future evaluation of the
physiological roles of CHDPs as key components of innate
antiviral host defences and to develop synthetic analogues
as novel antiviral therapeutics. The precise mechanisms
involved clearly vary in a peptide- and virus-specific
manner, from direct effects on the viruses through to pri-
marily immunomodulatory properties. These need to be
examined in detail and tested in vivo against specific viral
infections. Such research is expected to reveal therapeutic
strategies that range from simple administration of more
potent antiviral and/or immunomodulatory analogues, to
therapeutic measures to enhance natural levels of expres-
sion, replace down-regulated peptides or provide peptide at
an earlier, critical ‘‘tipping point’’ stage in infection.
Although some peptides may prove to be effective when
administered after infection is established, the optimal use
of other peptide therapeutics may be prophylactic admin-
istration in high-risk populations (e.g. infants and elderly in
an outbreak of a novel influenza strain for which a vaccine
is not available).
Challenges remain in optimising peptide therapeutics to
develop the shortest, cheapest analogues that are stable and
function at lower concentrations, in physiological envi-
ronments, without cytotoxic effects or the generation of
resistance. In this regard, the h-defensins appear particu-
larly exciting as potential topical anti-HIV agents. They are
well tolerated, certain members of the family appear to
function in the presence of serum, they rapidly and directly
kill HIV-1 without inducing large-scale immune activation
and escape variants are infrequent.
Engineering of peptides is a simple process, which
enables development of more suitable compounds. The
difference in the antiviral capabilities and RC50 values of
HNP1 and 3, despite them differing by only a single amino
acid, hints at what is possible. The engineering of RC101
from RC1 (again a single amino acid change) leading to
significantly higher anti-HIV-1 activity also suggests that
further enhancements should be possible. Likewise, linear,
disulphide bond-free defensins have been generated [148],
which retain potent antimicrobial activity. The develop-
ment of linear peptides would be significantly easier than
recreating their tertiary structure. However, the stability of
such peptides against protease degradation remains uncer-
tain and loss of antiviral properties following linearisation
has been described in some instances [18, 94], highlighting
the need for further research. Thus, in an era of increasing
concern about the resurgent threats of infectious diseases,
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a very limited repertoire of antiviral drugs and fears about the
rapidity with which new viruses can spread globally, peptide
therapeutics have potential that is clearly worth pursuing.
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